Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.

Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, Dolan S, Plante RK, Lau CY, Chang J.

Oncologist. 2006 Jan;11(1):73-82. Review. Erratum in: Oncologist. 2006 Apr;11(4):420.

4.

The effect of Epoetin alfa on quality of life in anemic cancer patients.

Cella D, Bron D.

Cancer Pract. 1999 Jul-Aug;7(4):177-82. Review.

PMID:
10687582
5.

Treatment of cancer-related anemia with epoetin alfa: a review.

Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E.

Cancer Treat Rev. 2004 Oct;30(6):563-75. Review.

PMID:
15325036
6.

Interventions for anemia in pediatric cancer patients.

Ruggiero A, Riccardi R.

Med Pediatr Oncol. 2002 Oct;39(4):451-4. Review.

PMID:
12203662
7.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly..

Eur J Cancer. 2007 Jan;43(2):258-70. Review.

PMID:
17182241
8.

Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.

Cortesi E, Gascón P, Henry D, Littlewood T, Milroy R, Pronzato P, Reinhardt U, Shasha D, Thatcher N, Wilkinson P.

Oncology. 2005;68 Suppl 1:22-32. Review.

PMID:
15855813
9.

Epoetin alfa in cancer patients: evidence-based guidelines.

Turner R, Anglin P, Burkes R, Couture F, Evans W, Goss G, Grimshaw R, Melosky B, Paterson A, Quirt I; Canadian Cancer and Anemia Guidelines Development Group..

J Pain Symptom Manage. 2001 Nov;22(5):954-65. Review.

PMID:
11728799
10.

The blue cross blue shield assessment technology review: summary of findings.

Bennett CL.

Best Pract Res Clin Haematol. 2005;18(3):423-31. Review.

PMID:
15792916
11.
12.

Experience with epoetin alfa and acquired immunodeficiency syndrome anemia.

Henry DH.

Semin Oncol. 1998 Jun;25(3 Suppl 7):64-8. Review.

PMID:
9671334
13.
14.

Epoetin alfa as a supportive measure in hematologic malignancies.

Straus DJ.

Semin Hematol. 2002 Oct;39(4 Suppl 3):25-31. Review.

PMID:
12447849
15.

The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy.

Dunst J.

Semin Oncol. 2001 Apr;28(2 Suppl 8):42-8. Review.

PMID:
11395852
16.

Impact of epoetin alfa in chemotherapy-associated anemia.

Jilani SM, Glaspy JA.

Semin Oncol. 1998 Oct;25(5):571-6. Review.

PMID:
9783596
17.

Management of cancer-related anemia: epoetin alfa and quality of life.

Soignet S.

Semin Hematol. 2000 Oct;37(4 Suppl 6):9-13. Review.

PMID:
11068950
18.

Is there a place for epoetin alfa in managing anemia during critical illness?

Givens M, Lapointe M.

Clin Ther. 2004 Jun;26(6):819-29. Review.

PMID:
15262453
19.

Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.

Crouch Z, DeSantis ER.

Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214. Review.

PMID:
19535656
20.

Epoetin alfa: into the new millennium.

Adamson JW.

Semin Oncol. 1998 Jun;25(3 Suppl 7):76-9. Review.

PMID:
9671336
Items per page

Supplemental Content

Support Center